Annual Financial Report 2022 and Notice of AGM
20 March 2023: Haleon plc (the "Company") (LSE/NYSE: HLN) today announces that the following documents have been made available to shareholders:
1. Annual Report and Form 20-F 2022
2. Notice of 2023 Annual General Meeting (AGM)
3. Form of Proxy for the 2023 AGM
4. AGM Voting Instruction Card
A copy of each of the documents has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism .
The Company will also file the Annual Report and Form 20-F 2022 with the US Securities and Exchange Commission today.
The documents referred to above are publicly available on the Company's website at www.haleon.com .
In compliance with the Disclosure Guidance and Transparency Rules, the Annual Report and Form 20-F 2022, as submitted to the National Storage Mechanism, contains regulated information in unedited full text and is available on the Company's website as noted above.
Shareholders may request a hard copy of the Annual Report and Form 20-F 2022, including the complete audited financial statements of the Company, free of charge from: Company Secretariat, Haleon plc, Building 5, First Floor, The Heights, Weybridge, KT13 0NY, United Kingdom.
Amanda Mellor, Company Secretary
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.